BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 9829294)

  • 1. Regional action of brofaromine on rat brain MAO-A and MAO-B.
    Gerardy J; Dresse A
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 Oct; 22(7):1141-55. PubMed ID: 9829294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of neurochemical effects of the monoamine oxidase inhibitors phenelzine, moclobemide and brofaromine in the rat after short- and long-term administration.
    Urichuk LJ; Allison K; Holt A; Greenshaw AJ; Baker GB
    J Affect Disord; 2000 May; 58(2):135-44. PubMed ID: 10781703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo evidence for the reversible action of the monoamine oxidase inhibitor brofaromine on 5-hydroxytryptamine release in rat brain.
    Bel N; Artigas F
    Naunyn Schmiedebergs Arch Pharmacol; 1995 May; 351(5):475-82. PubMed ID: 7543977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetrahydroaminoacridine inhibits human and rat brain monoamine oxidase.
    Adem A; Jossan SS; Oreland L
    Neurosci Lett; 1989 Dec; 107(1-3):313-7. PubMed ID: 2616041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newer aspects of the reversible inhibitor of MAO-A and serotonin reuptake, brofaromine.
    Waldmeier PC
    Prog Neuropsychopharmacol Biol Psychiatry; 1993 Mar; 17(2):183-98. PubMed ID: 8430214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of brofaromine, a reversible MAO-A inhibitor, on extracellular serotonin in the raphe nuclei and frontal cortex of freely moving rats.
    Celada P; Bel N; Artigas F
    J Neural Transm Suppl; 1994; 41():357-63. PubMed ID: 7931251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The inhibition of monoamine oxidase by brofaromine.
    Anderson MC; Waldmeier PC; Tipton KF
    Biochem Pharmacol; 1991 Jun; 41(12):1871-7. PubMed ID: 2039542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brofaromine: a monoamine oxidase-A and serotonin uptake inhibitor.
    Waldmeier PC; Glatt A; Jaekel J; Bittiger H
    Clin Neuropharmacol; 1993; 16 Suppl 2():S19-24. PubMed ID: 8313393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
    Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats.
    Kettler R; Da Prada M; Burkard WP
    Acta Psychiatr Scand Suppl; 1990; 360():101-2. PubMed ID: 2248058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversible, amine--selective effects of acute and chronic brofaromine treatment in the rat.
    Dyck LE; Boulton AA
    Life Sci; 1992; 51(1):59-66. PubMed ID: 1614274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors.
    Da Prada M; Kettler R; Keller HH; Burkard WP; Haefely WE
    J Neural Transm Suppl; 1989; 28():5-20. PubMed ID: 2677242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A and B forms of monoamine oxidase within the monoaminergic neurons of the rat brain.
    Fagervall I; Ross SB
    J Neurochem; 1986 Aug; 47(2):569-76. PubMed ID: 3734795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding of [3H]brofaromine to monoamine oxidase A in vivo: displacement by clorgyline and moclobemide.
    Waldmeier PC; Stöcklin K
    Eur J Pharmacol; 1990 May; 180(2-3):297-304. PubMed ID: 2365007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of rat brainstem monoamine oxidase activity by CGP 6085 A.
    Hurst JH; Kulakowski EC
    Life Sci; 1986 Oct; 39(16):1471-7. PubMed ID: 2430159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversibility of the interaction of CGP 11305 A with MAO A in vivo.
    Waldmeier PC; Feldtrauer JJ; Stoecklin K; Paul E
    Eur J Pharmacol; 1983 Oct; 94(1-2):101-8. PubMed ID: 6197309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline.
    Gerardy J
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):793-802. PubMed ID: 7938567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoamine oxidase-inhibiting properties of SR 95191, a new pyridazine derivative, in the rat: evidence for selective and reversible inhibition of monoamine oxidase type A in vivo but not in vitro.
    Kan JP; Steinberg R; Leclercq J; Worms P; Biziere K
    J Neurochem; 1988 Apr; 50(4):1137-44. PubMed ID: 3346672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The reversible MAO inhibitor, brofaromine, inhibits serotonin uptake in vivo.
    Waldmeier PC; Stöcklin K
    Eur J Pharmacol; 1989 Oct; 169(2-3):197-204. PubMed ID: 2806381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic TVP-1012 (rasagiline) dose--activity response of monoamine oxidases A and B in the brain of the common marmoset.
    Götz ME; Breithaupt W; Sautter J; Kupsch A; Schwarz J; Oertel WH; Youdim MB; Riederer P; Gerlach M
    J Neural Transm Suppl; 1998; 52():271-8. PubMed ID: 9564627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.